H1B Salary Data

Home › Employers › Northwest Infectious Disease Consultants SC

Northwest Infectious Disease Consultants SC: H-1B salaries and sponsorship

Northwest Infectious Disease Consultants SC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $215,000.

Applications (LCAs)3
Certified3
Employer addressNiles, IL
H-1B dependent employerNo
Median offered salary$215,000
Middle half of salaries$215,000–$215,000
10th–90th percentile$215,000–$215,000

Does Northwest Infectious Disease Consultants SC sponsor H-1B visas?

Northwest Infectious Disease Consultants SC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Oct 20, 2023. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Infectious Disease Physician3$215,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20232$215,000
FY20241$215,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Infectious Disease Physician$215,000
Level III
Park Ridge, ILOct 20, 2023Nov 13, 2023Certified
Infectious Disease Physician$215,000
Level III
Chicago, ILSep 3, 2023Oct 2, 2023Certified
Infectious Disease Physician$215,000
Level III
Chicago, ILAug 18, 2023Oct 2, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).